Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VNDA logo VNDA
Upturn stock ratingUpturn stock rating
VNDA logo

Vanda Pharmaceuticals Inc (VNDA)

Upturn stock ratingUpturn stock rating
$4.43
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VNDA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12.67

1 Year Target Price $12.67

Analysts Price Target For last 52 week
$12.67 Target price
52w Low $3.81
Current$4.43
52w High $5.54

Analysis of Past Performance

Type Stock
Historic Profit -46.62%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 261.76M USD
Price to earnings Ratio -
1Y Target Price 12.67
Price to earnings Ratio -
1Y Target Price 12.67
Volume (30-day avg) 3
Beta 0.72
52 Weeks Range 3.81 - 5.54
Updated Date 08/15/2025
52 Weeks Range 3.81 - 5.54
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-07-29
When Before Market
Estimate -0.2933
Actual -0.46

Profitability

Profit Margin -32.9%
Operating Margin (TTM) -73.21%

Management Effectiveness

Return on Assets (TTM) -9.88%
Return on Equity (TTM) -13.01%

Valuation

Trailing PE -
Forward PE 30.3
Enterprise Value -52147155
Price to Sales(TTM) 1.29
Enterprise Value -52147155
Price to Sales(TTM) 1.29
Enterprise Value to Revenue 0.59
Enterprise Value to EBITDA 12.91
Shares Outstanding 59089100
Shares Floating 49364241
Shares Outstanding 59089100
Shares Floating 49364241
Percent Insiders 7.21
Percent Institutions 78.74

ai summary icon Upturn AI SWOT

Vanda Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Vanda Pharmaceuticals Inc. was founded in 2002. It is a biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs.

business area logo Core Business Areas

  • Hetlioz: Hetlioz (tasimelteon) is a selective melatonin receptor agonist indicated for Non-24-Hour Sleep-Wake Disorder in adults and Smith-Magenis Syndrome in children.
  • Fanapt: Fanapt (iloperidone) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

leadership logo Leadership and Structure

Vanda's leadership team includes Mihael H. Polymeropoulos, M.D., as Chairman, President and CEO. The organizational structure follows a typical biopharmaceutical model with departments for research and development, commercial operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Hetlioz: Hetlioz (tasimelteon) is indicated for Non-24-Hour Sleep-Wake Disorder (N24HSWD) and Smith-Magenis Syndrome. Market share data is not publicly available but the primary competitor in the N24HSWD space is off-label melatonin use. Revenue from Hetlioz accounted for a substantial portion of Vanda's total revenue.
  • Fanapt: Fanapt (iloperidone) is an atypical antipsychotic for schizophrenia. Fanapt competes with numerous other antipsychotics, including those from major pharmaceutical companies (e.g., risperidone, quetiapine). Market share information is not publicly available.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for sleep disorders and schizophrenia treatments is large and growing.

Positioning

Vanda is a specialty pharmaceutical company focusing on niche markets with unmet needs. Its competitive advantage lies in its focus on specific indications and its expertise in developing and commercializing therapies for these indications.

Total Addressable Market (TAM)

The total addressable market for sleep disorders and schizophrenia is significant, estimated to be in the billions of dollars. Vanda is positioned to capture a portion of this market through its targeted therapies.

Upturn SWOT Analysis

Strengths

  • Specialized product portfolio targeting unmet medical needs
  • Established sales and marketing infrastructure
  • Strong intellectual property protection for key products

Weaknesses

  • Reliance on a limited number of products
  • Limited financial resources compared to larger pharmaceutical companies
  • Dependence on successful clinical trials and regulatory approvals

Opportunities

  • Expansion into new indications for existing products
  • Acquisition or licensing of new therapies
  • Geographic expansion into international markets

Threats

  • Competition from generic or biosimilar products
  • Unfavorable regulatory changes
  • Product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • ABBV
  • TEVA

Competitive Landscape

Vanda competes with large pharmaceutical companies. Its competitive advantage lies in its focus on niche markets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by sales of Hetlioz and Fanapt.

Future Projections: Future growth projections are based on analyst estimates which include sales forecasts for existing products and potential new product approvals.

Recent Initiatives: Recent initiatives include clinical trials for new indications and efforts to expand market access for existing products.

Summary

Vanda Pharmaceuticals is a biopharmaceutical company with a specialized product portfolio, focusing on niche markets. Its strengths include established products and intellectual property. However, it faces the challenge of reliance on a limited product line and competition from larger players. Vanda needs to focus on expanding its pipeline and maintaining strong regulatory relationships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vanda Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Washington, DC, United States
IPO Launch date 2006-04-12
Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 368
Full time employees 368

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.